EGTX Share Price Performance
SEK 4.96
1.29 (35.15%)
49.3% undervalued intrinsic discount
SEK 9.78
Fair Value
Price SEK 4.96
AnalystConsensusTarget SEK 9.78
AnalystHighTarget SEK 14.50
AnalystLowTarget SEK 1.60
Fair ValueSEK 9.78
Share Pricen/a
Egetis Therapeutics AB (publ) Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
EGTX Community Narratives
AN
Fair Value SEK 9.78 49.3% undervalued intrinsic discount
Rare Disease Approvals And Rising Diagnostic Awareness Will Transform This Biotech’s Long-Term Outlook
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value SEK 14.5 65.8% undervalued intrinsic discount
Bullish View Sees Regulatory Momentum And Global Access Infrastructure Driving Long Term Upside
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value SEK 1.6 210.0% overvalued intrinsic discount
Single Indication Reliance And Rising Payer Pressures Will Constrain Future Prospects
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Bullish View Sees Regulatory Momentum And Global Access Infrastructure Driving Long Term Upside
Catalysts About Egetis Therapeutics Egetis Therapeutics is a specialty pharmaceutical company focused on developing and commercializing Emcitate, tiratricol, for patients with MCT8 deficiency. What are the underlying business or industry changes driving this perspective?Read more
9
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
SEK 14.5
65.8% undervalued intrinsic discount
Fair Value
Profit Margin
40.94%
Future PE
7.93x
Price in 2029
SEK 16.9
Single Indication Reliance And Rising Payer Pressures Will Constrain Future Prospects
Catalysts About Egetis Therapeutics Egetis Therapeutics develops and commercializes treatments for rare endocrine and genetic disorders, with a focus on MCT8 deficiency. What are the underlying business or industry changes driving this perspective?Read more
5
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
SEK 1.6
210.0% overvalued intrinsic discount
Fair Value
Profit Margin
17.97%
Future PE
12.85x
Price in 2029
SEK 1.86
Rare Disease Approvals And Rising Diagnostic Awareness Will Transform This Biotech’s Long-Term Outlook
Catalysts About Egetis Therapeutics Egetis Therapeutics is a specialty biopharmaceutical company focused on developing and commercializing innovative treatments for patients with rare endocrine and metabolic disorders. What are the underlying business or industry changes driving this perspective?Read more
8
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
SEK 9.78
49.3% undervalued intrinsic discount
Fair Value
Profit Margin
19.7%
Future PE
19.92x
Price in 2028
SEK 11.39
Trending Discussion
Recently Updated Narratives
AN
Bullish View Sees Regulatory Momentum And Global Access Infrastructure Driving Long Term Upside
Fair Value: SEK 14.5 65.8% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Single Indication Reliance And Rising Payer Pressures Will Constrain Future Prospects
Fair Value: SEK 1.6 210.0% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rare Disease Approvals And Rising Diagnostic Awareness Will Transform This Biotech’s Long-Term Outlook
Fair Value: SEK 9.78 49.3% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Egetis Therapeutics AB (publ) Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Apr 29, 2026
- -0.87
- 19.87%
- -548.88%
- 22.6%
About EGTX
- Founded
- 2006
- Employees
- 42
- CEO
- WebsiteView website
Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. The company’s products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, a debilitating rare disease with no available treatment. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.
